Zitong Wan’s research while affiliated with Air Force Engineering University and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (4)


Figure 1 Central image. The figure on the left illustrates the diagnostic approaches for malignant lung nodules; the figure on the right depicts the methods employed for prognosis assessment of malignant lung nodules. CT, computed tomography; PET, positron emission tomography; CTC, circulating tumor cell; ctDNA, circulating tumor DNA; PD-1, programmed cell death 1; PD-L1, programmed death ligand 1; TIL, tumor infiltrating lymphocyte.
Precise diagnosis and prognosis assessment of malignant lung nodules: a narrative review
  • Literature Review
  • Full-text available

November 2024

·

8 Reads

Journal of Thoracic Disease

Miaomiao Wen

·

Qian Zheng

·

Xiaohong Ji

·

[...]

·

Yanlu Xiong

Background and Objective Pulmonary nodules (PNs) are small (≤3 cm) radiographic opacities within lung parenchyma. The use of low-dose computed tomography (LDCT) has led to a significant increase in the identification of solitary nodules. Malignant lung nodules comprise only 5% of all nodules, with management differing greatly from benign cases. Despite diagnostic advancements, there is heterogeneity in prognosis, which can result in undertreatment of high-risk patients and inappropriate treatment for low-risk patients. Therefore, accurately distinguishing benign from malignant nodules and effectively stratifying the risk of malignant nodules is a pressing clinical challenge requiring urgent resolution. The main objectives of this review were to explore the research progress in the clinical management of malignant PNs, including early detection, individualized treatment, and prognosis prediction, in order to shed light on precision medicine for patients with PNs. Methods The review examined various approaches for the identification and prognosis prediction of early lung cancer characterized by lung nodules, including the use of classical clinicopathological features, liquid biopsy, and artificial intelligence. Key Content and Findings The detection rate of early lung cancer characterized by lung nodules is increasing annually, and accurate identification and prognosis prediction are critical for appropriate therapeutic strategies and precise postoperative management. Classical clinicopathological features, such as demographic and radiological features, play an important role in the diagnosis and prognosis assessment of early lung cancer, but liquid biopsy and artificial intelligence are also promising due to their obvious convenience and accuracy. Conclusions The review highlights the importance of precision medicine in the clinical management of malignant lung nodules. The use of classical clinicopathological features, liquid biopsy, and artificial intelligence can contribute to the early detection, individualized treatment, and accurate prognosis prediction for patients with lung nodules, ultimately improving their clinical outcomes.

Download

Diagnosis and management of multiple primary lung cancer

Multiple primary lung cancer (MPLC), can be categorized as synchronous multiple primary lung cancer (sMPLC) and metachronous multiple primary lung cancer (mMPLC), which are becoming increasingly common in clinical practice. A precise differential diagnosis between MPLC and intrapulmonary metastases (IPM) is essential for determining the appropriate management strategy. MPLC is primarily diagnosed through histology, imaging, and molecular methods. Imaging serves as an essential foundation for preoperative diagnosis, while histology is a critical tool for establishing a definitive diagnosis. As molecular biology advances, the diagnosis of MPLC has stepped into the era of molecular precision. Surgery is the preferred treatment approach, with stereotactic radiotherapy and ablation being viable options for unresectable lesions. Targeted therapy and immunotherapy can be considered for specific patients. A multidisciplinary team approach to evaluation and the application of combination therapy can benefit more patients. Looking ahead, the development of more authoritative guidelines will be instrumental in streamlining the diagnosis and management of MPLC.


TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway

May 2024

·

35 Reads

·

3 Citations

Translational Oncology

Objective This study aimed to investigate TCF19′s role in lung cancer development, specifically its involvement in the RAF/MEK/ERK signaling pathway. Methods Lung cancer tissue analysis revealed significant TCF19 overexpression. In vitro experiments using A549 and Hop62 cells with TCF19 overexpression demonstrated enhanced cell growth. Transgenic mouse models confirmed TCF19′s role in primary tumor development. Transcriptome sequencing identified altered gene expression profiles, linking TCF19 to RAF/MEK/ERK pathway activation. Functional assays elucidated underlying mechanisms, revealing increased phosphorylation of Raf1, MEK1/2, and ERK1/2. Inhibiting RAF1 or ERK through shRaf1 or ERK inhibitor reduced cell cycle-related proteins and inhibited TCF19-overexpressing cell growth. Results TCF19 was identified as an oncogene in lung carcinoma, specifically impacting the RAF/MEK/ERK pathway. Elevated TCF19 levels in lung cancer suggest targeting TCF19 or its associated pathways as a promising strategy for disease management. Conclusion This study unveils TCF19′s oncogenic role in lung cancer, emphasizing its modulation of the RAF/MEK/ERK pathway and presenting a potential therapeutic target for TCF19-overexpressing lung cancers.


Figure 3
Figure 5
Figures
TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway

January 2024

·

34 Reads

Objective This study aimed to investigate the role of TCF19 in lung cancer, focusing on its impact on the development and progression of tumors. Specifically, the objective was to elucidate the molecular mechanisms underlying TCF19-mediated effects, with a particular emphasis on its involvement in the RAF/MEK/ERK signaling pathway. Methods The research involved the analysis of lung cancer tissues to assess the expression levels of TCF19. In vitro experiments were conducted using lung cancer cells (A549 and Hop62) with TCF19 overexpression. Transgenic mouse models were employed to study the in vivo effects of TCF19 on the development of primary tumors. Transcriptome sequencing was performed to identify alterations in gene expression profiles, and further experiments were carried out to investigate the activation status of the RAF/MEK/ERK pathway. Functional assays, including cell cycle progression and the levels of cell cycle-associated proteins, were conducted to understand the underlying mechanisms. Results The research findings demonstrated significant overexpression of TCF19 in lung cancer tissues. In vitro experiments revealed that TCF19 overexpression stimulated the growth of lung cancer cells and facilitated the development of primary tumors in transgenic mice. Mechanistically, TCF19 overexpression was associated with an elevation in the Ras and MAPK signaling pathways, as indicated by increased phosphorylation of Raf1, MEK1/2, and ERK1/2 in A549 and Hop62 cells. However, the inhibition of RAF1 or ERK, either through shRaf1 or ERK inhibitor, led to a reduction in cell cycle-related proteins and inhibited cell growth in TCF19-overexpressing cells. Conclusion In conclusion, this study identified TCF19 as an oncogene in lung carcinoma. The research highlighted its specific impact on the RAF/MEK/ERK signaling pathway, offering insights into a novel aspect of the molecular cascade involved in lung cancer development. Targeting TCF19 or its associated signaling pathways may present a promising avenue for the management of lung cancer characterized by elevated TCF19 levels.

Citations (1)


... Lung cancer remains a major killer worldwide [1][2][3][4][5] . Small cell lung cancer (SCLC) represents a highly aggressive and treatment-resistant form of lung cancer that occurs in roughly 15% of all cases [6,7] . ...

Reference:

Advancement Opportunities and Endeavor of Innovative Targeted Therapies for Small Cell Lung Cancer
TCF19 promotes cell proliferation and tumor formation in lung cancer by activating the Raf/MEK/ERK signaling pathway

Translational Oncology